Annexin Pharmaceuticals AB (publ) (STO: ANNX)
Sweden
· Delayed Price · Currency is SEK 0.460
-0.010 (-2.13%)
Nov 19, 2024, 4:33 PM CET
ANNX Company Description
Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases.
It develops ANXV, a human recombinant protein. The company offers Annexin A5 to protect and repair blood vessels and counteract inflammation.
Annexin Pharmaceuticals AB (publ) was founded in 2014 and is based in Stockholm, Sweden.
Annexin Pharmaceuticals AB (publ)
| Country | Sweden |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Anders Haegerstrand |
Contact Details
Address: Kammakargatan 48 Stockholm, 111 60 Sweden | |
| Website | annexinpharma.com |
Stock Details
| Ticker Symbol | ANNX |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0009664154 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anders Haegerstrand M.D., Ph.D. | Chief Executive Officer |
| Susanne Andersson | Chief Financial Officer |
| Susan Suchdev | Chief Operating Officer |
| Dr. Anna Frostegård M.D., Ph.D. | Chief Scientific and Medical Officer |
| Ulrika Harndahl | Head of CMC |
| Dr. Mario Fsadni L.L.M., M.Sc. | Therapeutic Area Head of Ophthalmology |
| Dr. Alain Thibault M.D. | Head of Oncology of Therapy Area |